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Three sets of research criteria are available for diagnosis of Alzheimer’s disease in subjects with mild cognitive impairment: the
International Working Group-1, International Working Group-2, and National Institute of Aging-Alzheimer Association criteria.
We compared the prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage according to these
criteria. Subjects with mild cognitive impairment (n = 1607), 766 of whom had both amyloid and neuronal injury markers, were
recruited from 13 cohorts. We used cognitive test performance and available biomarkers to classify subjects as prodromal
Alzheimer’s disease according to International Working Group-1 and International Working Group-2 criteria and in the high
Alzheimer’s disease likelihood group, conﬂicting biomarker groups (isolated amyloid pathology or suspected non-Alzheimer patho-
physiology), and low Alzheimer’s disease likelihood group according to the National Institute of Ageing-Alzheimer Association
criteria. Outcome measures were the proportion of subjects with Alzheimer’s disease at the mild cognitive impairment stage and
progression to Alzheimer’s disease-type dementia. We performed survival analyses using Cox proportional hazards models.
According to the International Working Group-1 criteria, 850 (53%) subjects had prodromal Alzheimer’s disease. Their 3-year
progression rate to Alzheimer’s disease-type dementia was 50% compared to 21% for subjects without prodromal Alzheimer’s
disease. According to the International Working Group-2 criteria, 308 (40%) subjects had prodromal Alzheimer’s disease. Their
3-year progression rate to Alzheimer’s disease-type dementia was 61% compared to 22% for subjects without prodromal
Alzheimer’s disease. According to the National Institute of Ageing-Alzheimer Association criteria, 353 (46%) subjects were in
the high Alzheimer’s disease likelihood group, 49 (6%) in the isolated amyloid pathology group, 220 (29%) in the suspected non-
Alzheimer pathophysiology group, and 144 (19%) in the low Alzheimer’s disease likelihood group. The 3-year progression rate to
Alzheimer’s disease-type dementia was 59% in the high Alzheimer’s disease likelihood group, 22% in the isolated amyloid path-
ology group, 24% in the suspected non-Alzheimer pathophysiology group, and 5% in the low Alzheimer’s disease likelihood
group. Our ﬁndings support the use of the proposed research criteria to identify Alzheimer’s disease at the mild cognitive impair-
ment stage. In clinical settings, the use of both amyloid and neuronal injury markers as proposed by the National Institute of
Ageing-Alzheimer Association criteria offers the most accurate prognosis. For clinical trials, selection of subjects in the National
Institute of Ageing-Alzheimer Association high Alzheimer’s disease likelihood group or the International Working Group-2
prodromal Alzheimer’s disease group could be considered.
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Introduction
In recent years three sets of research criteria for diagnosis
of Alzheimer’s disease in subjects with mild cognitive im-
pairment (MCI) have been proposed: the International
Working Group (IWG)-1 (Dubois et al., 2007, 2010),
IWG-2 (Dubois et al., 2014), and National Institute of
Ageing-Alzheimer Association (NIA-AA) criteria (Albert
et al., 2011). The criteria include biomarkers of
Alzheimer’s disease pathology to increase the conﬁdence
that subjects with MCI have Alzheimer’s disease as under-
lying cause. However, they differ in the deﬁnition of MCI
and biomarker abnormality (Visser et al., 2012) (Table 1).
A direct comparison between the criteria is lacking and it
remains unclear which criteria are best to use.
The IWG criteria use the term prodromal Alzheimer’s
disease for diagnosis of Alzheimer’s disease and were de-
signed to serve as research criteria. The IWG-1 criteria re-
quire episodic memory impairment and at least one
abnormal Alzheimer’s disease biomarker. This biomarker
can be a topographical marker [i.e. medial temporal lobe
atrophy on MRI or parieto-temporal hypoperfusion on 18F-
ﬂuorodeoxyglucose (FDG)-PET] or a pathophysiological
marker (i.e. decreased CSF amyloid-b1-42, increased CSF
tau, or increased amyloid PET uptake) (Dubois et al.,
2007, 2010). The updated IWG-2 criteria require cognitive
impairment in any cognitive domain and either both
decreased CSF amyloid-b1-42 and increased tau, or
increased amyloid PET uptake (Dubois et al., 2014).
These criteria specify two subtypes: typical prodromal
Alzheimer’s disease if impairment on a memory test is
present; and atypical prodromal Alzheimer’s if only impair-
ment on a non-memory test is present. The NIA-AA criteria
use the term ‘mild cognitive impairment due to Alzheimer’s
disease’ and were designed for both clinical and research
use. They require cognitive impairment in any cognitive
domain and abnormal amyloid markers (i.e. decreased
CSF amyloid-b1-42 or increased amyloid PET uptake) or
neuronal injury markers (i.e. medial temporal lobe atrophy
on MRI, increased CSF tau, or parietotemporal hypoperfu-
sion on FDG-PET). They relate the number of abnormal
biomarkers to the likelihood that MCI is due to
Alzheimer’s disease (Albert et al., 2011) (Table 1).
Preliminary studies have shown that the IWG-1 and NIA-
AA criteria have a fair to good predictive ability for pro-
gression to Alzheimer’s disease-type dementia in subjects
with MCI (Bouwman et al., 2010; Oksengard et al.,
2010; Petersen et al., 2013; Prestia et al., 2013). The val-
idity of the IWG-2 criteria has not yet been tested. The aim
of the present study is to compare the IWG-1, IWG-2 and
NIA-AA criteria on prevalence and outcome of Alzheimer’s
disease at the MCI stage by means of a large multicentre
study.
Material and methods
Subjects
Subjects were recruited from ﬁve multicentre studies:
DESCRIPA (Visser et al., 2008), AddNeuroMed
(Lovestone et al., 2009), German Dementia Competence
Network (DCN; Kornhuber et al., 2009), the European
Alzheimer’s Disease Consortium (EADC)-PET (Morbelli
et al., 2012), and American Alzheimer’s Disease
Neuroimaging Initiative (ADNI-1) study (Mueller et al.,
2005; Supplementary material); and from eight centres of
the EADC: Amsterdam (van der Flier et al., 2014),
Antwerp (Van der Mussele et al., 2014), Brescia (Frisoni
et al., 2009), Coimbra (Baldeiras et al., 2008), Gothenburg
(Eckerstro¨m et al., 2010), Kuopio (Seppa¨la¨ et al., 2011),
Lie`ge (Bastin et al., 2010), and Lisbon (Maroco et al.,
2011). If a subject participated in more than one study,
we used data from the study with the longest follow-up.
Inclusion criteria of the present study were diagnosis of
MCI, availability of at least one of the following bio-
markers: amyloid-b1-42 and tau in CSF, qualitative or quan-
titative measures of medial temporal lobe atrophy on MRI
[visual rating scale (medial temporal lobe atrophy score) or
hippocampal volume], or cerebral glucose metabolism on
brain FDG-PET; and at least one clinical follow-up assess-
ment. Exclusion criteria were diagnosis of dementia at
baseline or any other vascular, somatic, psychiatric or
neurological disorder that might have caused the cognitive
impairment.
Clinical assessment
Clinical assessment was performed according to the routine
protocol at each site, including a clinical interview, Mini-
Mental State Examination scoring, and neuropsychological
assessment. Baseline diagnosis of MCI was made according
to the criteria of Petersen et al. (2004). Raw scores on
neuropsychological tests were converted to Z-scores at
each centre. Cognitive impairment was deﬁned as
Z-score5 1.5 standard deviation (SD) on at least one
cognitive test (Supplementary Table 1). Subjects with a
Z-score5 1.5 SD on a memory test were classiﬁed as
having amnestic MCI. Subjects with a Z-score5 1.5
SD on a non-memory test only were classiﬁed as having
non-amnestic MCI.
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Primary outcome measures were the proportion of
subjects with Alzheimer’s disease at the MCI stage based
on the IWG-1, IWG-2 and NIA-AA criteria and progres-
sion to Alzheimer’s disease-type dementia according to the
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (APA, 1994) and National Institute of
Neurological and Communicative Disorders and Stroke -
Alzheimer’s Disease and Related Disorders Association
criteria (McKhann et al., 1984). Secondary outcome meas-
ure was cognitive decline on the Mini-Mental State
Examination.
The medical ethics committee at each centre approved the
study. All subjects provided informed consent.
Biomarker assessment
Biomarker assessment was performed according to the rou-
tine protocol at each site. PET scans were rated centrally.
We used centre-speciﬁc cut-offs to deﬁne abnormal bio-
markers (Supplementary Table 2). Visual assessments of
medial temporal lobe atrophy on MRI and cerebral glucose
metabolism on FDG-PET were performed by experienced
clinicians who were blinded to clinical and CSF biomarker
data.
Subject classification
According to the IWG-1 criteria, subjects were classiﬁed as
‘prodromal Alzheimer’s disease’ if they had episodic
memory impairment and at least one abnormal biomarker.
This could be a topographical or pathophysiological
marker (Table 1). Although the IWG-1 criteria recom-
mended a cued recall test to deﬁne memory impairment,
such tests were not available for most studies and we
used non-cued memory tests as well. According to the
IWG-1 update of 2010, we deﬁned atypical prodromal
Alzheimer’s disease as non-amnestic MCI with abnormal
biomarkers in a post hoc analysis.
According to the IWG-2 criteria, subjects were classiﬁed
as ‘prodromal Alzheimer’s disease’ if they had impairment
in memory (typical prodromal Alzheimer’s disease) or non-
memory domains (atypical prodromal Alzheimer’s disease)
and abnormal CSF amyloid-b1-42 and tau biomarkers
(Table 1). In the main analysis we pooled typical and atyp-
ical prodromal Alzheimer’s disease but we also performed
analyses for each subgroup separately.
According to the NIA-AA criteria, we distinguished be-
tween amyloid (i.e. CSF amyloid-b1-42) and neuronal injury
markers (i.e. CSF tau, cerebral glucose metabolism on
FDG-PET, medial temporal lobe atrophy score or hippo-
campal volume). Subjects with MCI in any domain were
classiﬁed in the low Alzheimer’s disease likelihood group if
both amyloid and neuronal injury markers were normal, in
the high Alzheimer’s disease likelihood group if amyloid
and at least one neuronal injury marker were abnormal,
and in one of the two conﬂicting biomarker groups if the
amyloid marker was abnormal and neuronal injury mar-
kers normal [isolated amyloid pathology group (IAP)] or if
at least one neuronal injury marker was abnormal and the
amyloid marker normal [suspected non-Alzheimer patho-
physiology group (SNAP)] (Jack et al., 2012; Petersen
et al., 2013; Vos et al., 2013a). Of the subjects who had
only one biomarker available, subjects were classiﬁed in the
intermediate Alzheimer’s disease likelihood group if the
marker that was tested was abnormal and in the unin-
formative/inconclusive group if the marker was tested
normal (Table 1).
Statistical analyses
Statistical analyses were done with SPSS version 20.0 with
signiﬁcance set at P5 0.05. Baseline differences between
Table 1 Classification according to the IWG-1, IWG-2 and NIA-AA criteria
Criteria Definition
IWG-1 (2007)
No prodromal Alzheimer’s disease No memory impairment or normal biomarkers
Prodromal Alzheimer’s disease Memory impairment, at least one abnormal Alzheimer’s disease biomarker
IWG-2 (2014)
No prodromal Alzheimer’s disease Any cognitive impairment, normal CSF amyloid-b1-42 and/or tau or normal amyloid PET scan
a
Prodromal Alzheimer’s disease Any cognitive impairment, abnormal CSF amyloid-b1-42 and tau or abnormal amyloid PET scan
a
NIA-AA (2011)
Low Alzheimer’s disease likelihood group Any cognitive impairment, normal amyloid and neuronal injury markers
High Alzheimer’s disease likelihood group Any cognitive impairment, abnormal amyloid and neuronal injury markers
Conflicting IAP group Any cognitive impairment, abnormal amyloid and normal neuronal injury marker
Conflicting SNAP group Any cognitive impairment, normal amyloid and abnormal neuronal injury marker
Intermediate Alzheimer’s disease likelihood group Any cognitive impairment, one marker testedb and abnormal
Inconclusive/uninformative group Any cognitive impairment, one marker testedb and normal
Amyloid marker = CSF amyloid-b1-42; neuronal injury marker = CSF tau/medial temporal lobe atrophy score/hippocampal volume/FDG-PET, cognitive impairment is defined as
Z-score5 1.5.
aIn our study, CSF data are used for subject classification.
bIn our study, only neuronal injury markers were tested.
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the biomarker subgroups were analysed using ANOVA for
continuous variables and 2 tests or logistic regression
models for categorical variables. Cox proportional hazards
models were used to test the predictive ability for
Alzheimer’s disease-type dementia. The relation of the cri-
teria with change on the Mini-Mental State Examination
was assessed by slope analyses with general linear mixed
models including the baseline and last follow-up score.
The model was speciﬁed with a random intercept and
slope and with centre as a random effect because this
model provided the best 2 log-likelihood compared
with models with simpler covariance structures. All ana-
lyses were adjusted for age, gender, education and centre.
Additionally, we calculated the sensitivity, speciﬁcity, posi-
tive and negative predictive value, and Youden index (sen-
sitivity + speciﬁcity1) for Alzheimer’s disease-type
dementia after 3 years.
Results
Sample demographics
We included 1607 subjects with a mean follow-up of
2.4 years (SD 1.3, range 0.5–9). One thousand ﬁve hundred
and eleven subjects had a 1-year follow-up, 1069 a 2-year
follow-up, 594 a 3-year follow-up, 170 a 4-year follow-up,
70 a 5-year follow-up, and 44 subjects had a follow-up
longer than 5 years. Seven hundred and sixty-six subjects
had data on amyloid and neuronal injury markers (CSF
amyloid-b1-42 with CSF tau, medial temporal lobe, or
FDG-PET) and 841 subjects had data on only a neuronal
injury marker (medial temporal lobe n = 698; FDG-PET
n = 143). Supplementary Tables 3 and 4 show the number
of subjects for each biomarker by centre and the character-
istics for the total sample and separate biomarker groups.
Prevalence and outcome
Table 2 shows the classiﬁcation and characteristics of sub-
jects according to the criteria and Table 3 shows the out-
come according to the criteria classiﬁcation. Eight hundred
and ﬁfty (53%) subjects had prodromal Alzheimer’s disease
according to the IWG-1 criteria, and 308 (40%) subjects
according to the IWG-2 criteria, either typical or atypical
(Table 2). Subjects with prodromal Alzheimer’s disease
were more likely to progress to Alzheimer’s disease-type
dementia (Table 3 and Fig. 1) and showed a larger decline
on the Mini-Mental State Examination (Supplementary
Table 5 and Supplementary Fig. 1) than subjects without
prodromal Alzheimer’s disease.
According to the NIA-AA criteria, of the subjects with
amyloid and injury markers available, 353 (46%) subjects
were classiﬁed in the high Alzheimer’s disease likelihood
group, 49 (6%) in the IAP group, 220 (29%) in the
SNAP group, and 144 (19%) in the low Alzheimer’s dis-
ease likelihood group (Table 2). Of the subjects with only a
neuronal injury marker available, 459 (55%) were classi-
ﬁed in the intermediate Alzheimer’s disease likelihood
group and 382 (45%) in the inconclusive group. Subjects
in the high Alzheimer’s disease likelihood group were more
likely to progress to Alzheimer’s disease-type dementia than
subjects in all other groups (Table 3 and Fig. 1). When the
NIA-AA categories were dichotomized, subjects with high
Alzheimer’s disease likelihood had a higher progression rate
compared to subjects in the low Alzheimer’s disease likeli-
hood and conﬂicting biomarker groups and subjects in the
high Alzheimer’s disease likelihood and conﬂicting bio-
marker groups had a higher progression rate than subjects
in the low Alzheimer’s disease likelihood group
(Supplementary Table 5). The high and intermediate
Alzheimer’s disease likelihood groups showed a larger
decline on the Mini-Mental State Examination compared
to all other groups (Supplementary Table 6 and
Supplementary Fig. 1).
Head-to-head comparison of criteria
In the subgroup of subjects with both amyloid and injury
markers (n = 766), the Cox regression prediction model
showed a slightly better ﬁt for the NIA-AA criteria than
for the IWG-2 and IWG-1 criteria because the 2 log-like-
lihood or deviance (a measure for unexplained variance)
was lowest for the NIA-AA criteria (2906 versus 2926
and 2982, respectively). Table 4 shows the overlap in clas-
siﬁcation between the criteria by outcome after 3 years. The
requirement of memory impairment for IWG-1 prodromal
Alzheimer’s disease and the requirement of abnormal CSF
amyloid-b1-42 and tau markers for IWG-2 prodromal
Alzheimer’s disease resulted in differences in classiﬁcation
compared to the NIA-AA criteria. Furthermore, the NIA-
AA conﬂicting biomarker groups are considered prodromal
Alzheimer’s disease according to the IWG-1 criteria but not
according to the IWG-2 criteria. In subsequent analyses, we
dichotomized the NIA-AA criteria in two ways: (i) high
Alzheimer’s disease likelihood group versus conﬂicting
and low Alzheimer’s disease likelihood groups; and (ii)
high Alzheimer’s disease likelihood and conﬂicting groups
versus low Alzheimer’s disease likelihood group. Table 5
shows that the speciﬁcity and positive predictive value
were highest for IWG-2, whereas the sensitivity and nega-
tive predictive value were highest for NIA-AA (ii). NIA-AA
(i) showed the highest Youden index.
In the subgroup of subjects with only a neuronal injury
marker (n = 841), the Cox regression model ﬁt was slightly
better for IWG-1 (2 log-likelihood 3000) than for NIA-
AA (2 log-likelihood 3012). The speciﬁcity was higher
for IWG-1 than NIA-AA (Table 5).
Typical versus atypical Alzheimer’s
disease
Of the subjects without IWG-1 prodromal Alzheimer’s dis-
ease, subjects with non-amnestic MCI and abnormal
Comparing diagnostic research criteria BRAIN 2015: 138; 1327–1338 | 1331
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biomarkers (atypical prodromal Alzheimer’s disease accord-
ing to the IWG-1 update, n = 231) were more likely to
progress to Alzheimer’s disease-type dementia (3-year pro-
gression rate 31%) than subjects with amnestic or non-
amnestic MCI with normal biomarkers (n = 526, 3-year
progression 17%, hazard ratio = 1.9, 95% CI 1.3–2.7,
P50.0001; Supplementary Fig. 2). Subjects with IWG-2
atypical prodromal Alzheimer’s disease (n = 49) had a simi-
lar progression rate as subjects with IWG-2 typical pro-
dromal Alzheimer’s disease (n = 259; 3-year progression
rate 63 versus 61%, P = 0.78; Supplementary Fig. 2).
Progression to non-Alzheimer’s dis-
ease dementia
Using the IWG-2 criteria, progression to non-Alzheimer’s
disease dementia was higher for subjects without pro-
dromal Alzheimer’s disease than for subjects with pro-
dromal Alzheimer’s disease (Table 2; 3-year progression
rate 13% versus 3%; hazard ratio = 3.4, 1.3–8.8,
P = 0.011). Using the NIA-AA classiﬁcation, progression
to non-Alzheimer’s disease dementia was higher in the
low Alzheimer’s disease likelihood (3-year progression
Figure 1 Alzheimer’s disease-type dementia survival probability by the IWG-1, IWG-2 and NIA-AA criteria. The graphs
represent the Alzheimer’s disease-type dementia survival probability according to the IWG-1 (left), IWG-2 (middle), and NIA-AA (right) criteria,
adjusted for age, gender, education and centre. IWG-1: The group without prodromal Alzheimer’s disease represents subjects without memory
impairment and/or abnormal biomarker(s). The prodromal Alzheimer’s disease group represents subjects with memory impairment and at least
one abnormal biomarker. IWG-2: The group without prodromal Alzheimer’s disease represents subjects with normal CSF amyloid-b1-42 and/or
tau. The prodromal Alzheimer’s disease group represents subjects with abnormal CSF amyloid-b1-42 and tau. NIA-AA: The low Alzheimer’s
disease likelihood group represents subjects with normal amyloid and neuronal injury markers, the high Alzheimer’s disease likelihood group
represents subjects with both abnormal amyloid and neuronal injury markers, the IAP group is a conflicting biomarker group with an abnormal
amyloid marker and normal neuronal injury marker, the SNAP group is a conflicting biomarker group with an abnormal neuronal injury marker
and normal amyloid marker, the intermediate Alzheimer’s disease likelihood group represents subjects with an abnormal neuronal injury marker
without information on amyloid pathology, the inconclusive group represents subjects with a normal neuronal injury marker without information
on amyloid pathology. AD = Alzheimer’s disease.
Table 3 Alzheimer’s disease-type dementia survival probability by the IWG-1, IWG-2 and NIA-AA criteria
3-year progression rate to
Alzheimer’s disease-type dementia*
Hazard ratio**
(95% CI)
P-value
IWG-1
No prodromal Alzheimer’s disease 21% Reference
Prodromal Alzheimer’s disease 50% 3.0 (2.4–3.7) 50.0001
IWG-2
No prodromal Alzheimer’s disease 22% Reference
Prodromal Alzheimer’s disease 61% 4.0 (3.0–5.2) 50.0001
NIA-AA
Low Alzheimer’s disease likelihood group 5% Reference
High Alzheimer’s disease likelihood group 59% 14.4 (5.9–35.2) 50.0001
Conflicting IAP group 22% 4.6 (1.6–13.2) 0.0050
Conflicting SNAP group 24% 4.7 (1.8–11.9) 0.0011
Intermediate Alzheimer’s disease likelihood group 49% 10.2 (4.1–25.2) 50.0001
Uninformative/inconclusive group 21% 3.5 (1.4–8.8) 0.0079
*Estimated 3-year progression (cumulative incidence) rate to Alzheimer’s disease-type dementia, **Hazard ratios (95% CI) for progression to Alzheimer’s disease-type dementia
calculated using Cox regression analyses and corrected for baseline age, gender, education and centre.
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rate 14%) and SNAP (3-year progression 13%) groups
compared to the high Alzheimer’s disease likelihood and
inconclusive groups (3-year progression both 4%; Table
2; low: hazard ratio = 3.0, 1.3–6.9, P = 0.011 compared
to high, hazard ratio = 2.8, 1.2–6.5, P = 0.016 compared
to inconclusive; SNAP: hazard ratio = 2.6, 1.2–5.6,
P = 0.013 compared to high, hazard ratio = 2.5, 1.1–5.3,
P = 0.021 compared to inconclusive). Using the IWG-1 cri-
teria, no difference in progression to non-Alzheimer’s dis-
ease dementia was found between subjects without and
with prodromal Alzheimer’s disease (Table 2; 3-year pro-
gression rate 8% versus 7%; hazard ratio = 1.2, 0.8–1.9,
P = 0.35).
Effect of neuronal injury marker
Subject classiﬁcation based on an amyloid marker in com-
bination with CSF tau or with medial temporal lobe was
generally the same (Table 6). Of the subjects with an ab-
normal amyloid marker and two neuronal injury markers,
29% had only one injury marker abnormal, with tau being
more often abnormal than the medial temporal lobe (Table
7). Both these neuronal injury groups had a similar out-
come. Subjects with abnormal CSF amyloid-b1-42 and both
abnormal CSF tau and medial temporal lobe atrophy had a
higher progression rate to Alzheimer’s disease-type demen-
tia than those with only one abnormal neuronal injury
marker (68% versus 36–41%, P5 0 .0001). Similar ﬁnd-
ings were obtained in subjects with a normal amyloid
marker (Table 7).
SNAP characterization
Because the SNAP group showed a relatively high progres-
sion rate to Alzheimer’s disease-type dementia, we
investigated CSF amyloid-b1-42 levels between subjects with
and without progression by comparing how much amyloid-
b1-42 levels were above the cut-off. Analyses were restricted
to subjects for whom biomarkers were analysed by
ELISA (n = 185), as the number of subjects with suspected
Table 4 Overlap in subject classification according to the IWG-1, IWG-2 and NIA-AA criteria by outcome
after 3 years
NIA-AA
Amyloid and neuronal injury markers (n = 766) Only a neuronal injury marker (n = 841)
Low Alzheimer’s
disease likelihood
(n = 144)
High Alzheimer’s
disease likelihood
(n = 353)
Conflicting:
IAP
(n = 49)
Conflicting:
SNAP
(n = 220)
Intermediate
Alzheimer’s
disease likelihood
(n = 459)
Uninformative/
Inconclusive
(n = 382)
IWG-1 No prodromal
Alzheimer’s disease
144 (2%) 60 (45%) 19 (11%) 72 (11%) 80 (19%) 382 (12%)
Prodromal
Alzheimer’s disease
- 293 (49%) 30 (23%) 148 (20%) 379 (39%) -
IWG-2 No prodromal
Alzheimer’s disease
144 (2%) 45 (42%) 49 (18%) 220 (17%) NA NA
Prodromal
Alzheimer’s disease
- 308 (49%) - - NA NA
Results are total number of subjects (% of subjects with Alzheimer’s disease-type dementia after 3 years of follow-up).
NA = not applicable
Table 5 Predictive accuracy of the IWG-1, IWG-2 and NIA-AA criteria for Alzheimer’s disease-type dementia
after 3 years
Sample Sensitivity Specificity Positive predictive
value
Negative predictive
value
Youden index
Amyloid and neuronal injury markers
IWG-1 0.82 (0.77–0.87) 0.47 (0.43–0.51) 0.38 (0.34–0.43) 0.86 (0.83–0.90) 0.29 (0.22–0.35)
IWG-2 0.69 (0.63–0.75) 0.71 (0.67–0.75) 0.49 (0.43–0.55) 0.85 (0.82–0.88) 0.40 (0.33–0.47)
NIA-AA (i) high versus conflicting/low 0.77 (0.72–0.83) 0.66 (0.63–0.70) 0.48 (0.43–0.53) 0.88 (0.85–0.91) 0.44 (0.37–0.51)
NIA-AA (ii) conflicting/high versus low 0.99 (0.97–1.00) 0.26 (0.22–0.29) 0.35 (0.31–0.39) 0.98 (0.96–1.00) 0.24 (0.20–0.28)
Only a neuronal injury marker
IWG-1 0.71 (0.64–0.77) 0.63 (0.60–0.67) 0.39 (0.34–0.44) 0.87 (0.83–0.90) 0.34 (0.27–0.41)
NIA-AA inconclusive versus intermediate 0.78 (0.72–0.83) 0.53 (0.49–0.57) 0.36 (0.31–0.40) 0.88 (0.84–0.91) 0.31 (0.24–0.38)
Results are predictive accuracy for Alzheimer’s disease-type dementia after 3-year follow-up according to the criteria for the subgroup with amyloid and neuronal injury markers
(n = 766) and for the subgroup with only a neuronal injury marker (n = 841). For the IWG-1 and IWG-2 criteria, groups are defined as no prodromal Alzheimer’s disease versus
prodromal Alzheimer’s disease.
Youden index = sensitivity + specificity1.
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non-Alzheimer pathophysiology for whom biomarkers were
analysed by xMAP was relatively small (n = 35). Subjects
with SNAP who progressed to Alzheimer’s disease-type de-
mentia had amyloid-b1-42 levels closer to the cut-off than
subjects who did not progress and subjects who progressed
to non-Alzheimer’s disease dementia [158 (SD 142) above
the cut-off versus 336 (SD 257) and 381 (SD 259) pg/ml
above the cut-off, P5 0.0001; Fig. 2].
Discussion
This is the ﬁrst large-scale multicentre study to compare the
IWG-1, IWG-2 and NIA-AA criteria for prodromal
Alzheimer’s disease in subjects with MCI. We noted
marked differences between the criteria in Alzheimer’s
disease prevalence and predictive accuracy for Alzheimer’s
disease-type dementia.
The IWG criteria were designed to identify individuals
with a high probability of having Alzheimer’s disease for
research purposes. Indeed, we found relatively high pro-
gression rates for Alzheimer’s disease-type dementia in sub-
jects with prodromal Alzheimer’s disease but we found also
that a substantial part of the subjects not meeting pro-
dromal Alzheimer’s disease criteria progressed to
Alzheimer’s disease-type dementia. For the IWG-1 criteria,
we demonstrated that the high progression rate in subjects
without prodromal Alzheimer’s disease is likely due to the
presence of subjects with non-amnestic MCI with abnormal
biomarkers. For the IWG-2 criteria, we demonstrated that
this is likely due to the inclusion of subjects with IAP and
SNAP in this group. A remarkable ﬁnding was the similar
predictive accuracy of IWG-2 typical and atypical pro-
dromal Alzheimer’s disease. This corroborates a previous
Table 6 Classification based on amyloid marker and CSF tau or medial temporal lobe neuronal injury marker
IWG-1 criteria NIA-AA criteria
Normal
group
Amnestic mild
cognitive impairment
and at least one
marker +
Amyloid 
Injury 
Amyloid +
Injury +
Amyloid +
Injury 
Amyloid 
Injury +
CSF amyloid-b1-42 and tau, n = 766
Prevalence 327 (43%) 439 (57%) 198 (26%) 308 (40%) 94 (12%) 166 (22%)
Progression to Alzheimer’s disease-type dementia
at last follow-up
55 (17%) 215 (49%) 12 (6%) 186 (60%) 32 (34%) 40 (24%)
CSF amyloid-b1-42 and MTL, n = 544
Prevalence 240 (44%) 304 (56%) 156 (29%) 191 (35%) 102 (19%) 95 (18%)
Progression to Alzheimer’s disease-type dementia
at last follow-up
42 (18%) 158 (52%) 14 (9%) 122 (64%) 28 (28%) 36 (38%)
Results are prevalence and progression rate for subject classifications based on CSF amyloid-b1-42 and tau versus CSF amyloid-b1-42 and medial temporal lobe.
MTL = medial temporal lobe
Table 7 Classification based on amyloid marker and two neuronal injury markers
Amyloid marker Amyloid + (n = 286) Amyloid  (n = 258)
Neuronal injury markers Tau 
MTL 
Tau +
MTL 
Tau 
MTL +
Tau +
MTL +
Tau 
MTL 
Tau +
MTL 
Tau 
MTL +
Tau +
MTL +
Prevalence within amyloid subgroup 37 (13%) 58 (20%) 25 (9%) 168 (58%) 91 (35%) 65 (25%) 39 (15%) 63 (24%)
Prevalence in total group 37 (7%) 58 (11%) 25 (5%) 166 (31%) 91 (17%) 65 (12%) 39 (7%) 63 (12%)
Progression to Alzheimer’s disease-type
dementia at last follow-up
12 (32%) 24 (41%) 9 (36%) 113 (68%) 4 (4%) 10 (15%) 5 (13%) 23 (37%)
Results are prevalence and progression rate for subject classifications based on CSF amyloid-b1-42, tau and medial temporal lobe.
MTL=medial temporal lobe.
Figure 2 CSF amyloid-b1-42 levels above the cut-off in the
SNAP group by outcome. Results are CSF amyloid-b1-42 levels
above the cut-off of subjects with SNAP who had Alzheimer’s dis-
ease-type dementia, no dementia or non-Alzheimer’s disease de-
mentia at follow-up. As amyloid-b1-42 cut-offs were different for
different studies, we compared the amyloid-b1-42 levels above the
cut-off (deviation from the cut-off) and not overall amyloid-b1-42
levels. The bold line represents the mean CSF amyloid-b1-42 levels
above the cut-off. AD = Alzheimer’s disease, Aß = amyloid-b.
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study (Vos et al., 2013b) and supports the use of non-
amnestic MCI as Alzheimer’s disease clinical phenotype.
The NIA-AA criteria were designed both for research and
clinical purposes. The prognosis of the low, high and inter-
mediate Alzheimer’s disease likelihood subgroups nicely
ﬁtted with the proposed terminology.
In the subsample with both amyloid and neuronal injury
markers available, differences in sensitivity, speciﬁcity, posi-
tive predictive value, and negative predictive value between
the criteria can be explained by whether one or two bio-
markers needed to be abnormal. If both were required to
be abnormal (as was the case for IWG-2 and NIA-AA high
Alzheimer’s disease likelihood versus low Alzheimer’s dis-
ease likelihood and conﬂicting biomarker groups), positive
predictive value and speciﬁcity were high and sensitivity
and negative predictive value low, consistent with previous
ﬁndings (van Rossum et al., 2012). If one biomarker was
required abnormal (as was the case for IWG-1, NIA-AA
high Alzheimer’s disease-likelihood and conﬂicting bio-
marker groups versus low-Alzheimer’s disease-likelihood
group), positive predictive value and speciﬁcity were low
and sensitivity and negative predictive value high.
In the subsample with only a neuronal injury marker
available, the higher speciﬁcity for IWG-1 compared to
NIA-AA (intermediate Alzheimer’s disease likelihood
group versus inconclusive group) likely reﬂects the require-
ment of memory impairment for IWG-1 prodromal
Alzheimer’s disease. The progression rate to Alzheimer’s
disease-type dementia in the NIA-AA intermediate
Alzheimer’s disease likelihood group was similar to that
of the high Alzheimer’s disease likelihood group and sug-
gests that many subjects also had abnormal amyloid
markers
The relatively high progression rate (20%) for subjects
with SNAP is intriguing, as the biomarker proﬁle suggests
that non-Alzheimer’s disease pathology is likely (Petersen
et al., 2013). We found that subjects with SNAP who pro-
gressed to Alzheimer’s disease-type dementia had CSF
amyloid-b1-42 levels just above the cut-off. This indicates
that the amyloid-b1-42 cut-offs may have been too conser-
vative, although using a more lenient cut-off would also
lead to more false positives. Alternatively, it could be that
these subjects have comorbidities so that less amyloid path-
ology is needed to progress to Alzheimer’s disease-type
dementia. SNAP could also be an atypical form of
Alzheimer’s disease with less pronounced amyloid path-
ology. It is also possible that these subjects have non-
Alzheimer’s disease pathology with minimal amyloid
deposits and are misclassiﬁed as Alzheimer’s disease-type
dementia at follow-up.
Only a small group of subjects was classiﬁed in the IAP
group, likely because most subjects with Alzheimer’s dis-
ease already have neuronal injury at the MCI stage.
Approximately 20% of the subjects with IAP progressed
to Alzheimer’s disease-type dementia. A previous MCI
study did not ﬁnd any converters with IAP, although this
could be due to their relatively short follow-up (1 year;
Petersen et al., 2013). Studies with longer follow-up are
needed to see whether all subjects with IAP will eventually
progress to Alzheimer’s disease-type dementia or have some
amyloid pathology unrelated to Alzheimer’s disease.
Availability of only one biomarker is a common clinical
situation. As amyloid assessment is relatively invasive and
expensive, often only neuronal injury markers will be mea-
sured. In subjects with only injury markers, the prognostic
accuracy of the NIA-AA intermediate Alzheimer’s disease
likelihood and inconclusive groups was very similar to that
of the IWG-1 groups.
A higher progression rate to non-Alzheimer’s disease de-
mentia was found in subjects without IWG-2 prodromal
Alzheimer’s disease compared to those with prodromal
Alzheimer’s disease and in subjects in the NIA-AA low
Alzheimer’s disease likelihood and SNAP groups compared
to the high Alzheimer’s disease likelihood group. This is in-
line with what is expected based on the biomarker proﬁles.
In general, the progression rate to non-Alzheimer’s disease
dementia at follow-up was rather low, which could be be-
cause the cohorts were designed to study Alzheimer’s
disease.
We found that 29% of the subjects with abnormal CSF
amyloid-b1-42 and two neuronal injury markers (CSF tau
and MTL) had only one of the abnormal injury markers.
This is likely because the neuronal injury biomarkers meas-
ure different pathophysiologies, and abnormality in one
does not always mean that the other is abnormal as well,
at least at the MCI stage. Subjects with both abnormal
injury markers had higher Alzheimer’s disease progression
rates compared to those with only one abnormal injury
marker in combination with amyloid pathology. This is
in-line with previous studies (Scott et al., 2010; van
Rossum et al., 2012) and suggests that the former group
is further in the disease process or has a more aggressive
form of Alzheimer’s disease.
The lack of standardized biomarker cut-offs is a known
drawback in the ﬁeld. We applied centre-speciﬁc biomarker
cut-offs to correct for possible differences in lab procedures.
Use of the same CSF ELISA cut-off for all centres would
have led to essentially the same results (Supplementary
Table 7). Although the use of predeﬁned cut-offs likely
resulted in somewhat lower sensitivities and speciﬁcities
compared to other studies that used cut-offs deﬁned
within the sample, our study may better reﬂect the real
diagnostic accuracy of biomarkers/the criteria.
This study has several limitations. Because the ﬁndings
were based on memory clinic or research populations,
they may not be generalizable to other settings. For some
subjects a MRI assessment was not performed or data were
not provided to us, although this is normally part of clin-
ical routine. No autopsy data were available, which might
have led to misclassiﬁcation of Alzheimer’s disease.
Furthermore, we used retrospective data so centres used
different cognitive tests and biomarker protocols.
Although this reﬂects current clinical practice, it could
have introduced variability. Analyses for the largest cohorts
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separately showed some variability in prevalence and out-
come of Alzheimer’s disease in subjects with MCI
(Supplementary Tables 8 and 9). However, as this variabil-
ity is typically random, pooling data from all centres is
likely to balance out on average. Furthermore, as our
main aim was to compare the sets of criteria, variability
in operationalization will affect each of the criteria simi-
larly. Standardization of cognitive tests and biomarkers
will be an important goal to achieve in the future and
many initiatives have started working on this. But even
after standardization the criteria may still perform differ-
ently in speciﬁc settings. Because we used retrospective
data, access to tests that measure non-memory domains
was limited. Our operationalization of atypical prodromal
Alzheimer’s disease may therefore not entirely reﬂect the
clinical variants described in the IWG-2 criteria and may
be less sensitive to detect atypical cognitive proﬁles. While
the IWG-1 criteria recommended a cued recall test to deﬁne
memory impairment, such tests were not available for most
studies and we used non-cued memory tests as well. New
prospective studies should include a wider range of cogni-
tive tests to improve operationalization of the criteria. We
used CSF amyloid-b1-42 as amyloid marker while use of
amyloid-PET could have led to different results and
would be interesting in light of the IWG-2 criteria. The
major strengths of our study include the large sample size
of well-characterized subjects and relatively long follow-up.
Our ﬁndings have several implications. Although the IWG-
1, IWG-2 and NIA-AA criteria for prodromal Alzheimer’s
disease can all be used to select subjects for therapeutic trials
or clinical follow-up, as they all predict cognitive decline
with reasonable accuracy, a certain set of criteria may be
preferred for speciﬁc purposes. In clinical trials, a high con-
version rate is needed. If both amyloid and neuronal injury
markers are available, one could best select subjects accord-
ing to the IWG-2 prodromal Alzheimer’s disease group or
NIA-AA high Alzheimer’s disease likelihood group. This
means that subjects with any MCI can be included. If only
neuronal injury markers are available, the IWG-1 criteria
should be considered rather than the NIA-AA criteria be-
cause of the higher speciﬁcity due to requirement of amnestic
MCI for prodromal Alzheimer’s disease. In clinical settings,
a reﬁned prognosis is needed and exclusion of the disease is
important to reassure patients. The NIA-AA criteria will
then offer the most accurate prognosis. As Alzheimer’s dis-
ease at the MCI stage can manifest as non-memory impair-
ment, a broad deﬁnition of MCI should be applied.
IAP and SNAP are heterogeneous conditions with sub-
groups progressing to Alzheimer’s disease-type dementia
and further studies are needed to characterize these sub-
jects’ prognosis and underlying pathophysiology.
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